Topically Applied Bisphosphocin Nu-3 on Infected Diabetic Ulcers of Subjects With Type I or II Diabetes Mellitus
Status:
Completed
Trial end date:
2018-02-01
Target enrollment:
Participant gender:
Summary
Phase I/IIa, five cohort ascending dose with two dosing arms per cohort, study in Type I or
II diabetes mellitus subjects with a chronic infected diabetic ulcer defined as having a DUSS
score of 0 to 3 and DFI wound score of 1 to 3.